
NOVELIX (NOVELIX) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
223.5M
Gross Profit
5.7M
2.56%
Operating Income
1.7M
0.76%
Net Income
1.1M
0.48%
EPS (Diluted)
₹0.09
Balance Sheet Metrics
Total Assets
272.1M
Total Liabilities
96.7M
Shareholders Equity
175.4M
Debt to Equity
0.55
Cash Flow Metrics
Revenue & Profitability Trend
NOVELIX Income Statement From 2024 to 2025
Metric | 2025 | 2024 |
---|---|---|
Revenue | 307.2M | 42.2M |
Cost of Goods Sold | 295.7M | 38.4M |
Gross Profit | 11.4M | 3.9M |
Gross Margin % | 3.7% | 9.2% |
Operating Expenses | ||
Research & Development | - | - |
Selling, General & Administrative | 3.8M | 1.0M |
Other Operating Expenses | 3.9M | 2.2M |
Total Operating Expenses | 7.7M | 3.3M |
Operating Income | 1.1M | -1.5M |
Operating Margin % | 0.4% | -3.5% |
Non-Operating Items | ||
Interest Income | 159.6K | 2.0M |
Interest Expense | 0 | - |
Other Non-Operating Income | - | - |
Pre-tax Income | 1.2M | 212.6K |
Income Tax | 388.2K | 108.4K |
Effective Tax Rate % | 31.5% | 51.0% |
Net Income | 845.2K | 104.1K |
Net Margin % | 0.3% | 0.2% |
Key Metrics | ||
EBITDA | 1.7M | -748.2K |
EPS (Basic) | ₹0.09 | ₹0.01 |
EPS (Diluted) | ₹0.09 | ₹0.01 |
Basic Shares Outstanding | 9391111 | 8100000 |
Diluted Shares Outstanding | 9391111 | 8100000 |
Income Statement Trend
NOVELIX Balance Sheet From 2024 to 2025
Metric | 2025 | 2024 |
---|---|---|
Assets | ||
Current Assets | ||
Cash & Equivalents | 6.8M | 1.2M |
Short-term Investments | 70.2M | 25.0M |
Accounts Receivable | 181.4M | 133.6K |
Inventory | 8.4M | 11.9M |
Other Current Assets | 9.2K | - |
Total Current Assets | 269.3M | 41.3M |
Non-Current Assets | ||
Property, Plant & Equipment | 1.9M | 0 |
Goodwill | 102 | 100 |
Intangible Assets | 102 | 100 |
Long-term Investments | - | - |
Other Non-Current Assets | -379.9K | - |
Total Non-Current Assets | 2.7M | 32.4M |
Total Assets | 272.1M | 73.6M |
Liabilities | ||
Current Liabilities | ||
Accounts Payable | 93.0M | 30.0K |
Short-term Debt | 0 | - |
Current Portion of Long-term Debt | - | - |
Other Current Liabilities | 1.0K | 71.3K |
Total Current Liabilities | 96.7M | 101.4K |
Non-Current Liabilities | ||
Long-term Debt | 0 | - |
Deferred Tax Liabilities | 0 | 0 |
Other Non-Current Liabilities | -1.0K | - |
Total Non-Current Liabilities | 0 | 0 |
Total Liabilities | 96.7M | 101.4K |
Equity | ||
Common Stock | 99.5M | 81.0M |
Retained Earnings | -18.8M | -24.1M |
Treasury Stock | - | - |
Other Equity | - | - |
Total Shareholders Equity | 175.4M | 73.5M |
Key Metrics | ||
Total Debt | 0 | 0 |
Working Capital | 172.7M | 41.2M |
Balance Sheet Composition
NOVELIX Cash Flow Statement From 2024 to 2025
Metric | 2025 | 2024 |
---|---|---|
Operating Activities | ||
Net Income | 1.2M | 212.6K |
Depreciation & Amortization | - | - |
Stock-Based Compensation | - | - |
Working Capital Changes | -222.4M | -440.0K |
Operating Cash Flow | -221.3M | -2.3M |
Investing Activities | ||
Capital Expenditures | -1.1M | 184.6K |
Acquisitions | - | - |
Investment Purchases | - | - |
Investment Sales | 30.2M | - |
Investing Cash Flow | 29.1M | 184.6K |
Financing Activities | ||
Share Repurchases | - | - |
Dividends Paid | - | - |
Debt Issuance | - | - |
Debt Repayment | - | - |
Financing Cash Flow | 113.2M | - |
Free Cash Flow | -137.9M | -3.4M |
Net Change in Cash | -79.1M | -2.1M |
Cash Flow Trend
NOVELIX Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
65.57
Price to Book
2.27
Price to Sales
1.10
PEG Ratio
-0.54
Profitability Ratios
Profit Margin
1.04%
Operating Margin
0.76%
Return on Equity
0.48%
Return on Assets
0.31%
Financial Health
Current Ratio
2.79
Debt to Equity
0.00
Beta
0.28
Per Share Data
EPS (TTM)
₹0.61
Book Value per Share
₹17.59
Revenue per Share
₹48.35
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
novelix | 595.8M | 65.57 | 2.27 | 0.48% | 1.04% | 0.00 |
Entero Healthcare | 49.3B | 48.24 | 2.86 | 5.36% | 1.90% | 21.76 |
Royal Sense | 1.4B | 20.96 | 4.44 | 27.55% | 10.26% | 11.74 |
Amwill Health Care | 1.1B | 7.86 | 1.51 | 24.85% | 26.44% | 0.00 |
Trimurthi | 398.0M | 102.35 | - | 0.00% | 3.73% | - |
Zenlabs Ethica | 212.2M | 78.92 | 1.96 | 2.58% | 0.52% | 121.85 |
Financial data is updated regularly. All figures are in the company's reporting currency.